Manage episode 294334015 series 1919400
Mälarstig is currently responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public–private partnerships such as the SCALLOP consortium. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics.
In this podcast, hear Mälarstig discuss proteogenomics, an emerging approach that aims to advance basic, translational and clinical research. He will also explain why the drug discovery sector should take an interest in it, what insights can it provide to researchers and the opportunities it is creating for drug discovery companies.